Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

STING MARK Universal Fiducial Marker System

NCT: NCT05465161 · RECRUITING

NCT IDNCT05465161
StatusRECRUITING
Start Date2022-02-28
Completion2027-11-01

Brief Summary

Currently available fiducial marker and fiducial insertion strategies are rudimentary, imprecise, not compatible with multiple insertion catheters/needles and are overall unreliable. STING-MARK device is the first universal, fully detachable and non-premounted radiopaque fiducial device system. Allowing biopsy prior to insertion, STING-MARK is easily and reliably delivered through-the-needle to the tumor, in order to accurately pinpoint its location for image-guided therapies. This study aims at establishing proof of concept for STING-MARK, by demonstrating its usability, reproducibility, radio-opacity and retention in a variety of clinically-relevant ex vivo organ samples.

Frequently Asked Questions

What is STING MARK Universal Fiducial Marker System?

STING MARK Universal Fiducial Marker System is a clinical trial registered under NCT05465161. Current status: RECRUITING.

What is the status of NCT05465161?

The current status of NCT05465161 (STING MARK Universal Fiducial Marker System) is: RECRUITING.

When did STING MARK Universal Fiducial Marker System start?

STING MARK Universal Fiducial Marker System started on 2022-02-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.